Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Antibody-based therapies in patients with acute lymphoblastic leukemia

Shira Dinner, Michaela Liedtke

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 9–15.

https://doi.org/10.1182/asheducation-2018.1.9

Published: 2018

Journal Articles

Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients

Sergio Giralt, Eric Seifter

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 103–109.

https://doi.org/10.1182/asheducation-2018.1.103

Published: 2018

Journal Articles

Hypereosinophilic syndrome: approach to treatment in the era of precision medicine

Amy Klion

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 326–331.

https://doi.org/10.1182/asheducation-2018.1.326

Published: 2018

Journal Articles

Management of multiple myeloma in the relapsed/refractory patient

Pieter Sonneveld

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 508–517.

https://doi.org/10.1182/asheducation-2017.1.508

Published: 2017

Journal Articles

Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia

Lewis B. Silverman

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 259–264.

https://doi.org/10.1182/asheducation-2017.1.259

Published: 2017

Journal Articles

Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies

Shaji Kumar

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 518–524.

https://doi.org/10.1182/asheducation-2017.1.518

Published: 2017

Journal Articles

Toward personalized treatment in Waldenström macroglobulinemia

Jorge J. Castillo, Steven P. Treon

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 365–370.

https://doi.org/10.1182/asheducation-2017.1.365

Published: 2017

Journal Articles

Novel agents in follicular lymphoma: choosing the best target

Laurie H. Sehn

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 284–292.

https://doi.org/10.1182/asheducation-2016.1.284

Published: 2016

Journal Articles

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Andrew J. Yee, Noopur S. Raje

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 495–503.

https://doi.org/10.1182/asheducation-2016.1.495

Published: 2016

Journal Articles

Advances and practical use of monoclonal antibodies in multiple myeloma therapy

Hans C. Lee, Donna M. Weber

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 512–520.

https://doi.org/10.1182/asheducation-2016.1.512

Published: 2016

Journal Articles

Treatment of rare factor deficiencies in 2016

Flora Peyvandi, Marzia Menegatti

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 663–669.

https://doi.org/10.1182/asheducation-2016.1.663

Published: 2016

Journal Articles

Cold agglutinin disease

Sigbjørn Berentsen

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 226–231.

https://doi.org/10.1182/asheducation-2016.1.226

Published: 2016

Journal Articles

The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia

Daniel J. DeAngelo

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 400–405.

https://doi.org/10.1182/asheducation-2015.1.400

Published: 2015

Journal Articles

Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors

Paul E. Monahan

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 33–40.

https://doi.org/10.1182/asheducation-2015.1.33

Published: 2015

Journal Articles

Checkpoint blockade in lymphoma

Philippe Armand

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 69–73.

https://doi.org/10.1182/asheducation-2015.1.69

Published: 2015

Journal Articles

B-cell receptor pathway modulators in NHL

Kristie A. Blum

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 82–91.

https://doi.org/10.1182/asheducation-2015.1.82

Published: 2015

Journal Articles

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

Paul G. Richardson, Jacob P. Laubach, Nikhil C. Munshi, Kenneth C. Anderson

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 255–261.

https://doi.org/10.1182/asheducation-2014.1.255

Published: 2014

Journal Articles

Recent insights into the role of the contact pathway in thrombo-inflammatory disorders

Maurits L. van Montfoort, Joost C.M. Meijers

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 60–65.

https://doi.org/10.1182/asheducation.V2014.1.60.3882400

Published: 2014

Journal Articles

Therapeutic targeting of microenvironment in follicular lymphoma

Grzegorz S. Nowakowski, Stephen M. Ansell

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 169–173.

https://doi.org/10.1182/asheducation-2014.1.169

Published: 2014

Journal Articles

Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1 , SF3B1 , and TP53

Clive S. Zent, W. Richard Burack

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 119–124.

https://doi.org/10.1182/asheducation-2014.1.119

Published: 2014

NARROW

Antibody-based therapies in patients with acute lymphoblastic leukemia

Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients

Hypereosinophilic syndrome: approach to treatment in the era of precision medicine

Management of multiple myeloma in the relapsed/refractory patient

Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia

Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies

Toward personalized treatment in Waldenström macroglobulinemia

Novel agents in follicular lymphoma: choosing the best target

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Advances and practical use of monoclonal antibodies in multiple myeloma therapy

Treatment of rare factor deficiencies in 2016

Cold agglutinin disease

The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia

Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors

Checkpoint blockade in lymphoma

B-cell receptor pathway modulators in NHL

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

Recent insights into the role of the contact pathway in thrombo-inflammatory disorders

Therapeutic targeting of microenvironment in follicular lymphoma

Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1 , SF3B1 , and TP53

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only